The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Review of the Fialuridine (FIAU) Clinical Trials
Young, C. W.; Schneider, R.; Leyland-Jones, B.; Armstrong, D.; Tan, C. T.; Lopez, C.; Watanabe, K. A.; Fox, J. J.; Philips, F. S. 1983. Phase 1 evaluation of 2'fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpes virus infection. Cancer Research; 43: 5006.
Zarafonetis, C. J. D.; Riley, P. A.; Willis, P. W.; Power, L. H.; Werbelow, J.; Farhat, L.; Beckwith, W.; Marks, B. H. 1978. Clinically significant adverse effects in a Phase I testing program. Clinical Pharmacology and Therapeutics; 24(2): 127-132.
